Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2849759

N[C@@H](CCCCNc1ncccc1[N+](=O)[O-])C(=O)N1CCSC1.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.59
DPP7 Q9UHL4 7/20 0.59
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
LMNA P02545 1/20 0.44
NPC1 O15118 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASP3 P42574 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2856502 0.87 DPP4 (0.52) DPP4DPP7DPP8DPP9
SCHEMBL2858856 0.79 DPP4 (0.52) DPP4DPP7DPP8DPP9NPC1
SCHEMBL2858860 0.79 DPP4 (0.52) DPP4DPP7DPP8DPP9NPC1
SCHEMBL2849762 0.78 DPP4 (0.52) DPP4DPP7DPP8DPP9LMNA
SCHEMBL2859952 0.78 DPP4 (0.51) DPP4DPP7DPP8DPP9CYP2D6
SCHEMBL2859960 0.78 DPP4 (0.51) DPP4DPP7DPP8DPP9CYP2D6
SCHEMBL2859755 0.77 DPP4 (0.58) DPP4DPP7DPP8DPP9
SCHEMBL2859760 0.77 DPP4 (0.58) DPP4DPP7DPP8DPP9
SCHEMBL2850241 0.76 DPP4 (0.53) DPP4DPP7DPP8DPP9MAPT
SCHEMBL2850239 0.76 DPP4 (0.53) DPP4DPP7DPP8DPP9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP4 1/4885DPP7 2/4885DPP8 5/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP4 1/4885DPP7 2/4885DPP8 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.